---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023496"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:52:43.567425+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering

## Summary
- Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).
- Cash $7.3M at June 30; $5.3M net from August 1 equity offering (6.052M shares at $0.95).
- Rebranded as Dyadic Applied BioSolutions; targeting 2025 commercial launch of animal-free serum albumin with Proliant.
- Received $1.5M second installment from Gates Foundation mAb grant; expects $500K Proliant milestone in Q3 2025.
- Inzymes milestone $250K received; EN3ZYME enzyme cocktail launched with Fermbox Bio under revenue share.

## SEC filing metadata
- accession: 0001641172-25-023496
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000164117225023496/0001641172-25-023496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000164117225023496/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023496
- JSON: https://secwatch.observer/filing/0001641172-25-023496.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.